Full Text Journal Articles by
Author Ajjai Alva

Advertisement

Find full text journal articles






Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, Nobuaki Matsubara, Lajos Géczi, Susanna Y-S Cheng, Yves Fradet, Stephane Oudard, Christof Vulsteke, Rafael Morales Barrera, Aude Fléchon, Seyda Gunduz, Yohann Loriot, Alejo Rodriguez-Vida, Ronac Mamtani, Evan Y Yu, Kijoeng Nam, Kentaro Imai, Blanca Homet Moreno, Ajjai Alva, ,

<h4>Background</h4>PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but positive randomised data supporting their use as a first-line treatment are lacking. In this study we assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemotherapy for patients with previously untreated advanced urothelial carcinoma.<h4>Methods</h4>KEYNOTE-361 is a randomised, ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2021, 22(7):931-945]

Cited: 1 time

View full text PDF listing >>



Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.

Praful Ravi, Gregory R Pond, Leonidas N Diamantopoulos, Christopher Su, Ajjai Alva, Rohit K Jain, William P Skelton, Sumati Gupta, Jonathan D Tward, Kathleen M Olson, Parminder Singh, Camilla M Grunewald, Guenter Niegisch, Jae-Lyun Lee, Andrea Gallina, Marco Bandini, Andrea Necchi, Matthew Mossanen, Bradley A McGregor, Catherine Curran, Petros Grivas, Guru P Sonpavde,

<h4>Objectives</h4>To evaluate outcomes of patients achieving a post-treatment pathological stage of <ypT2N0 at radical cystectomy (RC) following neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) to identify an optimal definition of pathological response.<h4>Patients and methods</h4>Patients from 10 international centres who underwent NAC for cT2-4aN0-1 MIBC and achieved <ypT2N0 disease at ... Read more >>

BJU Int (BJU international)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.

Lawrence Fong, Michael J Morris, Oliver Sartor, Celestia S Higano, Lance Pagliaro, Ajjai Alva, Leonard J Appleman, Winston Tan, Ulka Vaishampayan, Raphaelle Porcu, Darren Tayama, Edward E Kadel, Kobe C Yuen, Asim Datye, Andrew J Armstrong, Daniel P Petrylak,

<h4>Purpose</h4>Men with metastatic castration-resistant prostate cancer (mCRPC) have limited treatment options after progressing on hormonal therapy and chemotherapy. Here, we evaluate the safety and efficacy of atezolizumab (anti-PD-L1) + radium-223 dichloride (radium-223) in men with mCRPC.<h4>Patients and methods</h4>This phase Ib study evaluated atezolizumab + radium-223 in men with mCRPC and ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response.

Yuping Zhang, Sathiya P Narayanan, Rahul Mannan, Gregory Raskind, Xiaoming Wang, Pankaj Vats, Fengyun Su, Noshad Hosseini, Xuhong Cao, Chandan Kumar-Sinha, Stephanie J Ellison, Thomas J Giordano, Todd M Morgan, Sethuramasundaram Pitchiaya, Ajjai Alva, Rohit Mehra, Marcin Cieslik, Saravana M Dhanasekaran, Arul M Chinnaiyan,

Diverse subtypes of renal cell carcinomas (RCCs) display a wide spectrum of histomorphologies, proteogenomic alterations, immune cell infiltration patterns, and clinical behavior. Delineating the cells of origin for different RCC subtypes will provide mechanistic insights into their diverse pathobiology. Here, we employed single-cell RNA sequencing (scRNA-seq) to develop benign and ... Read more >>

Proc Natl Acad Sci U S A (Proceedings of the National Academy of Sciences of the United States of America)
[2021, 118(24):]

Cited: 0 times

View full text PDF listing >>



A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY).

Kenneth J Pienta, Michael A Gorin, Steven P Rowe, Peter R Carroll, Frédéric Pouliot, Stephan Probst, Lawrence Saperstein, Mark A Preston, Ajjai S Alva, Akash Patnaik, Jeremy C Durack, Nancy Stambler, Tess Lin, Jessica Jensen, Vivien Wong, Barry A Siegel, Michael J Morris,

<h4>Purpose</h4>Prostate specific membrane antigen-targeted positron emission tomography/computerized tomography has the potential to improve the detection and localization of prostate cancer. OSPREY was a prospective trial designed to determine the diagnostic performance of <sup>18</sup>F-DCFPyL-positron emission tomography/computerized tomography for detecting sites of metastatic prostate cancer.<h4>Materials and methods</h4>Two patient populations underwent <sup>18</sup>F-DCFPyL-positron emission ... Read more >>

J Urol (The Journal of urology)
[2021, 206(1):52-61]

Cited: 1 time

View full text PDF listing >>



Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Ajjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, Susan Halabi, Damien Hansra, Carmen J Calfa, Maged F Khalil, Eugene R Ahn, Timothy L Cannon, Pamela Crilley, Julie G Fisher, Derrick S Haslem, Sagun Shrestha, Kaitlyn R Antonelli, Nicole L Butler, Sasha L Warren, Andrew L Rygiel, Shamika Ranasinghe, Suanna S Bruinooge, Richard L Schilsky,

<h4>Purpose</h4>The TAPUR Study is a phase II basket trial that aims to identify signals of antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known to be drug targets. Results in a cohort of patients with metastatic breast cancer (mBC) with high tumor mutational ... Read more >>

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2021, :JCO2002923]

Cited: 0 times

View full text PDF listing >>



Reply by Authors.

Kenneth J Pienta, Michael A Gorin, Steven P Rowe, Peter R Carroll, Frédéric Pouliot, Stephan Probst, Lawrence Saperstein, Mark A Preston, Ajjai S Alva, Akash Patnaik, Jeremy C Durack, Nancy Stambler, Tess Lin, Jessica Jensen, Vivien Wong, Barry A Siegel, Michael J Morris,

J Urol (The Journal of urology)
[2021, 206(1):61]

Cited: 0 times

View full text PDF listing >>



Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.

Erin F Cobain, Yi-Mi Wu, Pankaj Vats, Rashmi Chugh, Francis Worden, David C Smith, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F Schott, Megan E V Caram, Daniel F Hayes, Elena M Stoffel, Michelle F Jacobs, Chandan Kumar-Sinha, Xuhong Cao, Rui Wang, David Lucas, Yu Ning, Erica Rabban, Janice Bell, Sandra Camelo-Piragua, Aaron M Udager, Marcin Cieslik, Robert J Lonigro, Lakshmi P Kunju, Dan R Robinson, Moshe Talpaz, Arul M Chinnaiyan,

<h4>Importance</h4>Use of next-generation sequencing (NGS) to identify clinically actionable genomic targets has been incorporated into routine clinical practice in the management of advanced solid tumors; however, the clinical utility of this testing remains uncertain.<h4>Objective</h4>To determine which patients derived the greatest degree of clinical benefit from NGS profiling.<h4>Design, setting, and participants</h4>Patients ... Read more >>

JAMA Oncol (JAMA oncology)
[2021, 7(4):525-533]

Cited: 2 times

View full text PDF listing >>



De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome.

Eman Abdulfatah, Zachery R Reichert, Matthew S Davenport, Arul M Chinnaiyan, Vipulkumar Dadhania, Xiaoming Wang, Rahul Mannan, Lakshmi P Kunju, Brent K Hollenbeck, Jeffrey S Montgomery, Samuel D Kaffenberger, Todd M Morgan, Ajjai S Alva, Ganesh S Palapattu, Ulka N Vaishampayan, Joshi J Alumkal, Daniel E Spratt, Aaron M Udager, Rohit Mehra,

Neuroendocrine transdifferentiation of high-grade prostate cancer (PCA-NT) comprises a morphologic and immunophenotypic transition from conventional adenocarcinoma towards high-grade neuroendocrine/small cell carcinoma. This phenomenon is frequently observed post androgen deprivation and/or radiotherapy, but de novo instances are increasingly recognized. Herein, we report a series of de novo PCA-NT focusing on characteristic ... Read more >>

Med Oncol (Medical oncology (Northwood, London, England))
[2021, 38(3):26]

Cited: 0 times

View full text PDF listing >>



Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.

Stepan M Esagian, Ali Raza Khaki, Leonidas N Diamantopoulos, Lucia Carril-Ajuria, Daniel Castellano, Ivan De Kouchkovsky, Joseph J Park, Ajjai Alva, Mehmet A Bilen, Tyler F Stewart, Rana R McKay, Victor S Santos, Neeraj Agarwal, Jayanshu Jain, Yousef Zakharia, Rafael Morales-Barrera, Michael E Devitt, Ariel Nelson, Christopher J Hoimes, Evan Shreck, Benjamin A Gartrell, Alex Sankin, Abhishek Tripathi, Roubini Zakopoulou, Aristotelis Bamias, Alejo Rodriguez-Vida, Alexandra Drakaki, Sandy Liu, Vivek Kumar, Mark P Lythgoe, David J Pinato, Jure Murgic, Ana Fröbe, Monika Joshi, Pedro Isaacsson Velho, Noah Hahn, Lucia Alonso Buznego, Ignacio Duran, Marcus Moses, Pedro Barata, Matthew D Galsky, Guru Sonpavde, Evan Y Yu, Pavlos Msaouel, Vadim S Koshkin, Petros Grivas,

<h4>Objectives</h4>To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs).<h4>Patients and methods</h4>We performed a retrospective cohort study collecting clinicopathological, treatment, and outcome data for patients with aUC receiving ICIs from 2013 to 2020 ... Read more >>

BJU Int (BJU international)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.

Daniel H Kwon, Jonathan Chou, Steven M Yip, Melissa A Reimers, Li Zhang, Francis Wright, Mallika S Dhawan, Hala T Borno, Arpita Desai, Rahul R Aggarwal, Alexander W Wyatt, Eric J Small, Ajjai S Alva, Kim N Chi, Felix Y Feng, Vadim S Koshkin,

<h4>Background</h4>DNA damage repair mutations (DDRm) are common in patients with metastatic castration-resistant prostate cancer (mCRPC). The optimal standard therapy for this population is not well described.<h4>Methods</h4>A multi-institutional, retrospective study of patients with mCRPC and DDRm was conducted. Patient data, including systemic therapies and responses, were collected. The decline in prostate-specific ... Read more >>

Cancer (Cancer)
[2021, 127(12):1965-1973]

Cited: 0 times

View full text PDF listing >>



Antisense oligonucleotides and nucleic acids generate hypersensitive platelets.

Alexander Zaslavsky, Mackenzie Adams, Xiu Cao, Adriana Yamaguchi, James Henderson, Peter Busch-Østergren, Aaron Udager, Sethuramasundaram Pitchiaya, Benjamin Tourdot, Tadas Kasputis, Samuel J Church, Samantha K Lee, Sydney Ohl, Shivam Patel, Todd M Morgan, Ajjai Alva, Thomas W Wakefield, Zachery Reichert, Michael Holinstat, Ganesh S Palapattu,

<h4>Introduction</h4>Despite the great promise for therapies using antisense oligonucleotides (ASOs), their adverse effects, which include pro-inflammatory effects and thrombocytopenia, have limited their use. Previously, these effects have been linked to the phosphorothioate (PS) backbone necessary to prevent rapid ASO degradation in plasma. The main aim of this study was to ... Read more >>

Thromb Res (Thrombosis research)
[2021, 200:64-71]

Cited: 0 times

View full text PDF listing >>



Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.

Jessica J Waninger, Vincent T Ma, Sara Journey, Jeremy Skvarce, Zoey Chopra, Alangoya Tezel, Alex K Bryant, Charles Mayo, Yilun Sun, Kamya Sankar, Nithya Ramnath, Christopher Lao, Jeremy B Sussman, Leslie Fecher, Ajjai Alva, Michael D Green,

<h4>Importance</h4>Immune checkpoint inhibitors (ICIs) have transformed the survival of patients with metastatic melanoma. Patient prognosis is reflected by the American Joint Committee on Cancer (AJCC) staging system; however, it is unknown whether the metastatic (M) stage categories for cutaneous melanoma remain informative of prognosis in patients who have received ICIs.<h4>Objectives</h4>To ... Read more >>

JAMA Netw Open (JAMA network open)
[2021, 4(3):e210980]

Cited: 0 times

View full text PDF listing >>



LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.

Landon C Brown, Matthew D Tucker, Ramy Sedhom, Eric B Schwartz, Jason Zhu, Chester Kao, Matthew K Labriola, Rajan T Gupta, Daniele Marin, Yuan Wu, Santosh Gupta, Tian Zhang, Michael R Harrison, Daniel J George, Ajjai Alva, Emmanuel S Antonarakis, Andrew J Armstrong,

<h4>Background</h4>Low-density lipoprotein receptor-related protein 1b (encoded by <i>LRP1B</i>) is a putative tumor suppressor, and preliminary evidence suggests <i>LRP1B-</i>mutated cancers may have improved outcomes with immune checkpoint inhibitors (ICI).<h4>Methods</h4>We conducted a multicenter, retrospective pan-cancer analysis of patients with <i>LRP1B</i> alterations treated with ICI at Duke University, Johns Hopkins University (JHU) and ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2021, 9(3):]

Cited: 1 time

View full text PDF listing >>



A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.

Ali Raza Khaki, Ang Li, Leonidas N Diamantopoulos, Natalie J Miller, Lucia Carril-Ajuria, Daniel Castellano, Ivan De Kouchkovsky, Vadim Koshkin, Joseph Park, Ajjai Alva, Mehmet A Bilen, Tyler Stewart, Victor Santos, Neeraj Agarwal, Jayanshu Jain, Yousef Zakharia, Rafael Morales-Barrera, Michael Devitt, Ariel Nelson, Christopher J Hoimes, Evan Shreck, Benjamin A Gartrell, Alex Sankin, Abhishek Tripathi, Roubini Zakopoulou, Aristotelis Bamias, Alejo Rodriguez-Vida, Alexandra Drakaki, Sandy Liu, Vivek Kumar, Mark P Lythgoe, David J Pinato, Jure Murgic, Ana Fröbe, Monika Joshi, Pedro Isaacsson Velho, Noah Hahn, Lucia Alonso Buznego, Ignacio Duran, Marcus Moses, Pedro Barata, Matthew D Galsky, Guru Sonpavde, Evan Y Yu, Veena Shankaran, Gary H Lyman, Petros Grivas,

<h4>Background</h4>While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L) setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for platinum (cisplatin/carboplatin)-unfit patients, response rates remain modest and outcomes vary with no clinically useful biomarkers (except for PD-L1).<h4>Objective</h4>We aimed to develop a prognostic model for overall survival ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, 4(3):464-472]

Cited: 0 times

View full text PDF listing >>



A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.

Sumanta K Pal, Catherine Tangen, Ian M Thompson, Naomi Balzer-Haas, Daniel J George, Daniel Y C Heng, Brian Shuch, Mark Stein, Maria Tretiakova, Peter Humphrey, Adebowale Adeniran, Vivek Narayan, Georg A Bjarnason, Ulka Vaishampayan, Ajjai Alva, Tian Zhang, Scott Cole, Melissa Plets, John Wright, Primo N Lara,

<h4>Background</h4>MET (also known as hepatocyte growth factor receptor) signalling is a key driver of papillary renal cell carcinoma (PRCC). Given that no optimal therapy for metastatic PRCC exists, we aimed to compare an existing standard of care, sunitinib, with the MET kinase inhibitors cabozantinib, crizotinib, and savolitinib for treatment of ... Read more >>

Lancet (Lancet (London, England))
[2021, 397(10275):695-703]

Cited: 5 times

View full text PDF listing >>



A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695).

Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, Ajjai Alva, Seth P Lerner, M Scott Lucia, David J McConkey, Dan Theodorescu, Amir Goldkorn, Matthew I Milowsky, Rick Bangs, Gary R MacVicar, Bruno R Bastos, Jared S Fowles, Daniel L Gustafson, Melissa Plets, Ian M Thompson,

<h4>Purpose</h4>Dose-dense methotrexate-vinblastine-adriamycin-cisplatin (ddMVAC) and gemcitabine-cisplatin (GC) are accepted neoadjuvant regimens for muscle-invasive bladder cancer. The aim of this study was to validate the score from a coexpression extrapolation (COXEN) algorithm-generated gene expression model (GEM) as a biomarker in patients undergoing radical cystectomy.<h4>Patients and methods</h4>Eligibility included cT2-T4a N0 M0, urothelial bladder ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, 27(9):2435-2441]

Cited: 2 times

View full text PDF listing >>



Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2.

Joseph I Clark, Brendan Curti, Elizabeth J Davis, Howard Kaufman, Asim Amin, Ajjai Alva, Theodore F Logan, Ralph Hauke, Gerald P Miletello, Ulka Vaishampayan, Douglas B Johnson, Richard L White, Peter H Wiernik, Janice P Dutcher,

High-dose interleukin-2 (HD IL-2) was approved in the 1990s after demonstrating durable complete responses (CRs) in some patients with metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC). Patients who achieve this level of disease control have also demonstrated improved survival compared with patients who progress, but limited data are ... Read more >>

J Investig Med (Journal of investigative medicine : the official publication of the American Federation for Clinical Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care.

Nathan A Pennell, Melissa Dillmon, Laura A Levit, E Allyn Moushey, Ajjai S Alva, Sibel Blau, Timothy L Cannon, Natalie R Dickson, Maximilian Diehn, Mithat Gonen, Maria Magdalena Gonzalez, Jack O Hensold, Leslie J Hinyard, Tari King, Stacie C Lindsey, Allison Magnuson, Jonathan Marron, Barbara L McAneny, Theresa M McDonnell, Kathryn Finch Mileham, Shelley Fuld Nasso, Grzegorz S Nowakowski, Kurt R Oettel, Manali I Patel, Debra A Patt, Jane Perlmutter, Todd A Pickard, Gladys Rodriguez, Abby R Rosenberg, Barry Russo, Connie Szczepanek, Cardinale B Smith, Piyush Srivastava, Eleonora Teplinsky, Ramya Thota, Tiffany A Traina, Robin Zon, Brian Bourbeau, Suanna S Bruinooge, Shelagh Foster, Stephen Grubbs, Karen Hagerty, Patricia Hurley, Deborah Kamin, Jonathan Phillips, Caroline Schenkel, Richard L Schilsky, Howard A Burris,

This report presents the American Society of Clinical Oncology's (ASCO's) evaluation of the adaptations in care delivery, research operations, and regulatory oversight made in response to the coronavirus pandemic and presents recommendations for moving forward as the pandemic recedes. ASCO organized its recommendations for clinical research around five goals to ... Read more >>

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2021, 39(2):155-169]

Cited: 6 times

View full text PDF listing >>



Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance.

Heng Lin, Ilona Kryczek, Shasha Li, Michael D Green, Alicia Ali, Reema Hamasha, Shuang Wei, Linda Vatan, Wojciech Szeliga, Sara Grove, Xiong Li, Jing Li, Weichao Wang, Yijian Yan, Jae Eun Choi, Gaopeng Li, Yingjie Bian, Ying Xu, Jiajia Zhou, Jiali Yu, Houjun Xia, Weimin Wang, Ajjai Alva, Arul M Chinnaiyan, Marcin Cieslik, Weiping Zou,

Immunotherapy induces durable clinical responses in a fraction of patients with cancer. However, therapeutic resistance poses a major challenge to current immunotherapies. Here, we identify that expression of tumor stanniocalcin 1 (STC1) correlates with immunotherapy efficacy and is negatively associated with patient survival across diverse cancer types. Gain- and loss-of-function ... Read more >>

Cancer Cell (Cancer cell)
[2021, 39(4):480-493.e6]

Cited: 3 times

View full text PDF listing >>



Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.

Vincent T Ma, Christopher T Su, Miriam Hu, Jeremy M G Taylor, Stephanie Daignault-Newton, Olesia Kellezi, Megan N Dahl, Miloni A Shah, Stephanie Erickson, Jessica Lora, Reema Hamasha, Alicia Ali, Sabrina Yancey, Leah Kiros, Hannah M Balicki, Daniel C Winfield, Michael D Green, Ajjai S Alva,

<h4>Purpose</h4>Several immune checkpoint inhibitors (ICIs) are FDA approved for treatment of genitourinary (GU) malignancies. We aim to determine demographic and clinicopathologic characteristics that significantly affect clinical outcomes in patients with advanced stage GU malignancies treated with ICIs.<h4>Materials and methods</h4>We performed a single-center, consecutive, retrospective cohort analysis on patients with metastatic ... Read more >>

Urol Oncol (Urologic oncology)
[2021, 39(7):437.e1-437.e9]

Cited: 0 times

View full text PDF listing >>



Immunotherapy in metastatic sarcomatoid renal cell carcinoma: A single institution experience.

Joseph J Park, Olesia Kellezi, Reema Hamasha, Alicia Ali, Ajjai S Alva,

<h4>Introduction</h4>Immune checkpoint inhibitors (CPIs) were recently approved in advanced clear cell renal cell carcinoma (RCC) and could be a promising option for metastatic RCC with sarcomatoid differentiation (sRCC) which otherwise carry a poor prognosis. We sought to compare outcomes between patients who received immunotherapy (IO) including CPIs or high dose ... Read more >>

Cancer Treat Res Commun (Cancer treatment and research communications)
[2020, 25:100251]

Cited: 1 time

View full text PDF listing >>



Accelerating precision medicine in metastatic prostate cancer.

Joaquin Mateo, Rana McKay, Wassim Abida, Rahul Aggarwal, Joshi Alumkal, Ajjai Alva, Felix Feng, Xin Gao, Julie Graff, Maha Hussain, Fatima Karzai, Bruce Montgomery, William Oh, Vaibhav Patel, Dana Rathkopf, Matthew Rettig, Nikolaus Schultz, Matthew Smith, David Solit, Cora Sternberg, Eliezer Van Allen, David VanderWeele, Jake Vinson, Howard R Soule, Arul Chinnaiyan, Eric Small, Jonathan W Simons, William Dahut, Andrea K Miyahira, Himisha Beltran,

Despite advances in prostate cancer screening and treatment, available therapy options, particularly in later stages of the disease, remain limited and the treatment-resistant setting represents a serious unmet medical need. Moreover, disease heterogeneity and disparities in patient access to medical advances result in significant variability in outcomes across patients. Disease ... Read more >>

Nat Cancer (Nature cancer)
[2020, 1(11):1041-1053]

Cited: 0 times

View full text PDF listing >>



Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.

Jiali Yu, Michael D Green, Shasha Li, Yilun Sun, Sara N Journey, Jae Eun Choi, Syed Monem Rizvi, Angel Qin, Jessica J Waninger, Xueting Lang, Zoey Chopra, Issam El Naqa, Jiajia Zhou, Yingjie Bian, Long Jiang, Alangoya Tezel, Jeremy Skvarce, Rohan K Achar, Merna Sitto, Benjamin S Rosen, Fengyun Su, Sathiya P Narayanan, Xuhong Cao, Shuang Wei, Wojciech Szeliga, Linda Vatan, Charles Mayo, Meredith A Morgan, Caitlin A Schonewolf, Kyle Cuneo, Ilona Kryczek, Vincent T Ma, Christopher D Lao, Theodore S Lawrence, Nithya Ramnath, Fei Wen, Arul M Chinnaiyan, Marcin Cieslik, Ajjai Alva, Weiping Zou,

Metastasis is the primary cause of cancer mortality, and cancer frequently metastasizes to the liver. It is not clear whether liver immune tolerance mechanisms contribute to cancer outcomes. We report that liver metastases diminish immunotherapy efficacy systemically in patients and preclinical models. Patients with liver metastases derive limited benefit from ... Read more >>

Nat Med (Nature medicine)
[2021, 27(1):152-164]

Cited: 18 times

View full text PDF listing >>



The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.

Vincent T Ma, Stephanie Daignault-Newton, Jessica J Waninger, Sara Journey, Zoey Chopra, Alangoya Tezel, Bruce G Redman, Leslie A Fecher, Michael D Green, Ajjai S Alva, Christopher D Lao,

Nearly half of all metastatic melanoma patients possess the BRAF V600 mutation. Several therapies are approved for advanced stage melanoma, but it is unclear if there is a differential outcome to various immunotherapy regimens based on BRAF mutation status. We retrospectively analyzed a cohort of metastatic or unresectable melanoma patients ... Read more >>

Pigment Cell Melanoma Res (Pigment cell & melanoma research)
[2021, 34(3):629-640]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.2738 s